Skip to content

Released Nov 7, 2024, after the close

10-Q filed Nov 7, 2024, 38 days after period end · 0000950170-24-123402

Q3 2024 · 10-Q
Revenue$6.85M— vs Q3 2023−19.8% vs Q2 2024
Net Income-$9.61MN/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$1.51N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$10,956,000N/M
Operating Cash Flowderived-$15,244,000N/M
Free Cash Flowderived-$15,244,000N/M
Margins · derived
Operating margin-160.1%
Net margin-140.4%

What the release said

The release

Same quarter

MetricQ3 2024Q3 2023Q3 2022Q3 2021
Revenue$6.85M$0.00—$6.25M
Net Income-$9.61M-$14.42M-$23.15M-$18.80M
EPS Diluted-$1.51-$3.29-$0.48-$0.41

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR